- US-listed companies
- Adaptimmune Therapeutics PLC
- Income statement
Adaptimmune Therapeutics PLC (ADAPY) Income statement
Market cap
$5.73M
P/E ratio
| 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 14 | 38 | 60 | 1 | 4 | 6 | 27 | 60 | 178 |
| Revenue growth (%) | - | ||||||||
| Cost of revenue | - | - | - | - | - | - | - | - | 0 |
| Research & development | 64 | 87 | 98 | 98 | 92 | 111 | 128 | 127 | 149 |
| Selling, general & administrative | - | - | - | - | - | - | - | - | 87 |
| Operating margin (%) | |||||||||
| Operating expenses | 87 | 118 | 142 | 141 | 137 | 168 | 191 | 200 | 247 |
| Operating income | -73 | -81 | -82 | -140 | -133 | -162 | -164 | -140 | -69 |
| Income before tax | -71 | -70 | -95 | -137 | -130 | -157 | -163 | -113 | -67 |
| Pretax margin (%) | -497.9 | -184.2 | -159.7 | -12,203.5 | -3,282.7 | -2,558.1 | -600.3 | -186.7 | -37.8 |
| Provision for income taxes | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 4 |
| Effective tax rate (%) | |||||||||
| Net income | -72 | -70 | -96 | -137 | -130 | -158 | -165 | -114 | -71 |
| Net income margin (%) | |||||||||
| Earnings per share | - | - | - | - | - | -0.17 | -0.17 | -0.09 | -0.05 |
| Diluted EPS | - | - | - | - | - | -0.17 | -0.17 | -0.09 | -0.05 |